BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

LLY upcoming catalysts

Eli Lilly and Company: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 37 readout(s) and 16 FDA event(s). Subscribe to LLY (.ics).

Drugs: Tirzepatide, Retatrutide, Orforglipron, Abemaciclib, Temozolomide, Brenipatide, Tocilizumab, Semaglutide, Insulin Glargine

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Eli Lilly and Company LLYNCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerNausea; Vomiting; Drug-Related Side Effects and Adverse Reactions; Neoplasmsrecruiting204
2027-02 est.P2Eli Lilly and Company LLYNCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyGliomaactive not recruiting45
2027-02 est.P3Eli Lilly and Company LLYNCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Obesity; Overweightrecruiting125
2027-02 est.P2Eli Lilly and Company LLYNCT07223840 A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapseSmokingrecruiting222

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-09FDA approvalapprovedELI LILLY AND CO LLYOLUMIANTApproved 2026-10-09: OLUMIANT (NDA207924 SUPPL10)
2026-09-25FDA approvalapprovedELI LILLY AND CO LLYOLUMIANTApproved 2026-09-25: OLUMIANT (NDA207924 SUPPL9)
2026-09-23FDA approvalapprovedELI LILLY AND CO LLYONSWIKApproved 2026-09-23: ONSWIK (BLA761408 ORIG1)
2026-09-18FDA approvalapprovedELI LILLY AND CO LLYINLURIYOApproved 2026-09-18: INLURIYO (NDA218881 SUPPL1)
2026-09-18FDA approvalapprovedELI LILLY AND CO LLYVERZENIOApproved 2026-09-18: VERZENIO (NDA208716 SUPPL22)
2026-08-27FDA approvalapprovedELI LILLY AND CO LLYMOUNJARO MOUNJARO KWIKPENApproved 2026-08-27: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (NDA215866 SUPPL44)
2026-08-27FDA approvalapprovedELI LILLY AND CO LLYMOUNJARO MOUNJARO KWIKPENApproved 2026-08-27: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (NDA215866 SUPPL45)
2026-08-26FDA approvalapprovedELI LILLY AND CO LLYZEPBOUND ZEPBOUND KWIKPENApproved 2026-08-26: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (NDA217806 SUPPL41)
2026-07-14FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2026-07-14: RETEVMO (NDA218160 SUPPL7)
2026-07-14FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2026-07-14: RETEVMO (NDA213246 SUPPL17)
2026-07-13FDA approvalapprovedELI LILLY AND CO LLYVERZENIOApproved 2026-07-13: VERZENIO (NDA208716 SUPPL21)
2026-06-09FDA approvalapprovedELI LILLY AND CO LLYEBGLYSSApproved 2026-06-09: EBGLYSS (BLA761306 SUPPL6)
2026-04-01FDA approvalapprovedELI LILLY AND CO LLYFOUNDAYOApproved 2026-04-01: FOUNDAYO (NDA220934 ORIG1)
2025-12-19FDA approvalapprovedELI LILLY AND CO LLYMOUNJARO MOUNJARO KWIKPENApproved 2025-12-19: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (NDA215866 SUPPL39)
2025-11-20FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2025-11-20: RETEVMO (NDA218160 SUPPL6)
2025-11-20FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2025-11-20: RETEVMO (NDA213246 SUPPL15)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2Eli Lilly and Company LLYNCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar RemovalAcute Pain; Molar; Molar, Third; Surgery, Oralrecruiting212
2026-11 est.P2Eli Lilly and Company LLYNCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinDiabetes Mellitus, Type 2active not recruiting100
2026-11 est.P3Eli Lilly and Company LLYNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting465
2026-11 est.P3Eli Lilly and Company LLYNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting905
2026-11 est.P3Eli Lilly and Company LLYNCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityObesityactive not recruiting800
2026-10-26P3Eli Lilly and Company LLYNCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on BaType 2 Diabetesactive not recruiting341
2026-10-22P3Eli Lilly and Company LLYNCT06339008 A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Perennial Allergic Rhinitis (PAR)active not recruiting450
2026-10 est.P3Eli Lilly and Company LLYNCT04088396 A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Systemic Juvenile Idiopathic Arthritisactive not recruiting58
2026-08-27P3Eli Lilly and Company LLYNCT06260722 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Diabetes Mellitus, Type 2active not recruiting1250
2026-08-03P2Eli Lilly and Company LLYNCT06598943 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisUlcerative Colitis; Ulcerative Colitis Chronicactive not recruiting143
2026-07-21P3Eli Lilly and Company LLYNCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightOSA; Overweight or Obesitycompleted712
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07-01P2Eli Lilly and Company LLYNCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight WObesity; Overweightcompleted367
2026-06-16P3Eli Lilly and Company LLYNCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightType 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apneacompleted1152
2026-06-02P3Eli Lilly and Company LLYNCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweightactive not recruiting160
2026-05-13P3Eli Lilly and Company LLYNCT06921759 A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisAtopic Hand and Foot Dermatitiscompleted221
2026-05-01P2Eli Lilly and Company LLYNCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseAlzheimer Diseasecompleted304
2026-05-01P3Eli Lilly and Company LLYNCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisUlcerative Colitiscompleted63
2026-04-16P3Eli Lilly and Company LLYNCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseObesity; Cardiovascular Diseasescompleted1946
2026-04-06P3Eli Lilly and Company LLYNCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightObesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apneacompleted2335
2026-03-19P2Eli Lilly and Company LLYNCT06817356 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderAlcohol Use Disordercompleted308
2026-03-16P3Eli Lilly and Company LLYNCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased CardioType 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidneycompleted2749
2026-03-04P3Eli Lilly and Company LLYNCT03519945 A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Ulcerative Colitisactive not recruiting1058
2026-01-22P3Eli Lilly and Company LLYNCT06354660 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-TDiabetes Type 2completed537
2026-01-20P3Eli Lilly and Company LLYNCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesOverweight; Obesitycompleted441
2026-01-16P2Eli Lilly and Company LLYNCT06643728 A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightObesity; Overweightcompleted252
2026-01-14P3Eli Lilly and Company LLYNCT05559359 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis; Eczemaactive not recruiting377
2026-01-12P2Eli Lilly and Company LLYNCT06568042 Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyNeuropathic Pain; Distal Sensory Polyneuropathycompleted558
2026-01-12P3Eli Lilly and Company LLYNCT04819100 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell Lungactive not recruiting152
2026-01-08P3Eli Lilly and Company LLYNCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightPsoriasis; Obesitycompleted281
2026-01-08P2Eli Lilly and Company LLYNCT06037252 A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityType 2 Diabetes; Obesityactive not recruiting414
2026-01-07P2Eli Lilly and Company LLYNCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightObesity; Overweightcompleted288
2025-12-15P2Eli Lilly and Company LLYNCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityObesitycompleted392
2025-12-10P3Eli Lilly and Company LLYNCT04616326 A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineChronic Migraineactive not recruiting312
2025-12-08P2Eli Lilly and Company LLYNCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisRheumatoid Arthritiscompleted164
2025-12-04P3Eli Lilly and Company LLYNCT04396574 A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineMigraineterminated558
2025-11-21P3Eli Lilly and Company LLYNCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAObesity; Overweightcompleted376

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.